<DOC>
	<DOCNO>NCT00505076</DOCNO>
	<brief_summary>Patients schizophrenia characterize broad range neurocognitive abnormality . These include impairment attention , include abnormality sensory gating ; executive function ; visual verbal learn memory ; work memory ; process speed ; social cognition ( Nuechterlein et al , 2004 ) . These impairment major determinant poor functional outcome patient schizophrenia ( Green , 1996 ; Green et al , 2004 ) . Conventional antipsychotic limited effect impairment . Second generation antipsychotic may modest benefit cognitive function , whether represent direct cognitive enhance effect establish . Regardless , patient continue exhibit pronounced cognitive impairment despite adequate second generation antipsychotic treatment . Adjunctive pharmacotherapy may offer viable approach treatment cognitive impairment . Adjunctive agent use modulate specific neurotransmitter system hypothesize involved pharmacology cognitive function . The standard care schizophrenia antipsychotic medication treat psychotic symptom . However , cognitive impairment remain impairment find significantly associate poor psychosocial function observe patient schizophrenia . There considerable preclinical rationale use drug act Gamma-amino-buyric acid ( GABA ) α2 subunit adjunctive treatment target cognitive impairment . MK-0777 GEM ( Merck-0777 Gel Extrusion Module ) formulation provide opportunity directly test mechanism . The purpose propose study examine efficacy safety two dos MK ( Merck ) -0777 GEM , 3 mg BID ( twice daily ) 8 mg BID ( twice daily ) , treatment cognitive impairment patient schizophrenia . Secondary goal determine whether MK-0777 beneficial effect measure functional capacity patient self-report cognitive function .</brief_summary>
	<brief_title>Treatment Study Cognitive Deficits Schizophrenia</brief_title>
	<detailed_description>The propose study multicenter , randomize , double blind comparison MK-0777 GEM 3 mg BID , MK-0777 GEM 8 mg BID , placebo . The total sample consist 90 clinically stable patient DSM IV TR schizophrenia , 30 subject randomize group . A best estimate diagnostic approach utilize , information Structured Clinical Interview DSM-IV ( Diagnostic Statistical Manual Mental Disorders , Fourth Edition ) ( First et al , 1997 ) supplement information family informant , previous psychiatrist , medical record generate diagnosis . The projected number subject recruit site 12-13 . There 2 week , placebo lead-in evaluation phase , subject undergo baseline diagnostic ; medical , include physical examination , EKG ( electrocardiogram ) , CBC ( Complete Blood Count ) , complete metabolic panel , urine toxicology , UA ( urinalysis ) ; psychiatric ; neurocognitive , symptom level functional capacity patient self-report cognitive function assessment . In addition , subject receive slit-lamp eye examination . At end evaluation phase , subject randomize one two MK-0777 dos placebo . The double-blind treatment phase 4 week . Subjects receive bi-weekly symptom assessment weekly side effect vital sign assessment . At week 4 , subject undergo repeat administration neuropsychological test battery functional capacity patient self-report cognitive function measure . These assessment do two-day period . Subjects blood sample collect antipsychotic MK-0777 level week 4 . An EKG ( electrocardiogram ) obtain end double-blind study . Slit-lamp eye examination conduct study completion , 6 month 12 month study completion . After completion 4-week double-blind phase , 4-day follow-up phase subject taper study medication . Study Locations : The study conduct Treatment Units Research Neurocognition Schizophrenia ( TURNS ) study network , comprise seven site : Columbia University School Medicine ( P.I . : Jeffrey Lieberman , M.D . ) ; Duke University School Medicine ( P.I . : Joseph McEvoy , M.D . ) ; Harvard University School Medicine ( P.I . : Donald Goff , M.D . ) ; Maryland Psychiatric Research Center ( MPRC ) ( P.I . : Robert W. Buchanan , M.D . ) ; Nathan Kline Institute ( P.I . : Daniel Javitt , M.D . ) University California Los Angeles School Medicine ( P.I . : Steve Marder , M.D . ) ; Washington University School Medicine ( P.I . : John Csernansky , M.D. ) . The TURNS NIMH-funded contract evaluation new compound treatment cognitive impairment schizophrenia ( HHSN 27820044 1003C ; P.I . : Steve Marder , M.D. ) . Data management perform Clinical Trials Data Management Unit Nathan Kline Institute direction Jim Robinson , M.S. , statistical analysis perform Dr. Robert McMahon Maryland Psychiatric Research Center . Laboratory assay perform Quest Diagnostics . Procedures : Clinical Assessments : The symptom assessment include Brief Psychiatric Rating Scale ; Scale Assessment Negative Symptoms ( SANS ) ; Calgary Depression Scale ( CDS ) ; Clinical Global Impression Scale ( CGI ) . ) BPRS ( Brief Psychiatric Rating Scale ) : four positive symptom item ( conceptual disorganization , suspiciousness , hallucinatory behavior , unusual thought content ) use measure positive psychotic symptom . ii ) SANS ( Scale Assessment Negative Symptoms ) : SANS total score , minus global item , inappropriate affect , poverty content speech , attention item , use measure negative symptom . The inappropriate affect , poverty content speech , attention item exclude lack construct validity factor analytic study result suggest item closely related negative symptom . iii ) CDS ( Calgary Depression Scale ) : CDS total score use measure depressive symptom . iv ) CGI ( Clinical Global Impressions ) : CGI severity illness item use ass global change Safety Assessments : The safety assessment include Simpson Angus Extrapyramidal Symptom Rating Scale ( SAS ) ; Abnormal Involuntary Movement Scale ( AIMS ) ; Side Effect Checklist ( SEC ) . ) SAS : modify 11 item version SAS use assess EPS . ii ) AIMS : 12 item scale , 7 item design assess abnormal facial , oral , extremity , trunk movement ; 3 global judgment item ; 2 current dental status item . iii ) SEC : design ass vital sign , commonly occur antipsychotic side effect , side effect indicative uveitis cataract . Subjects ask adverse event visit , instruct call study site experience adverse event point study . Any serious adverse event , include death due cause , occur subject enter study within 14 day follow cessation treatment , whether related investigational product , report Merck &amp; Co. , Inc. within 24 hour . Functional Assessments : The functional assessment include UCSD Performance-Based Skills Assessment ( UPSA ) Schizophrenia Cognition Rating Scale ( SCoRS ) . ) UPSA : design ass skill five area : household chore , communication , finance , transportation , plan recreational activity . Subjects ask perform task area score accord ability complete task . The UPSA take 25 - 30 minute administer . ii ) SCoRS : rating scale design elicit information subject informant level cognitive function subject . The subject informant version 20 item . Subject informant interview take 10 - 15 minute complete . Neurocognitive Assessments : The NIMH MATRICS ( Measurement Treatment Research Improve Cognition Schizophrenia Research ) Neuropsychological Battery , Wechsler Test Adult Reading ( WTAR ) , N-Back test ; Continuous Performance Test ( CPT-AX ) use assess cognitive function . The NIMH MATRICS Neuropsychological Battery comprise measure : ) work memory ; b ) attention/vigilance ; c ) verbal memory ; ) visual memory ; e ) process speed ; f ) problem solve ; g ) social cognition . The N-Back CPT-AX computerized measure prefrontal cortex dependent cognitive behavior . Screening : The diagnosis schizophrenia confirm research psychiatrist use modify version Structured Clinical Interview DSM IV ( SCID ) . The BPRS , SANS , CDRS SAS administer verify inclusionary criterion meet . Subjects slit-lamp eye examination . 2 Week , Lead-in Evaluation Phase : In 2 week lead-in evaluation phase , subject receive placebo . They undergo baseline symptom , medical , safety , neurocognitive assessment . The subject undergo physical examination ; include neurological exam , EKG ; laboratory test major organ function ( i.e. , CBC ( complete blood count ) , liver function test , electrolyte , glucose , BUN/Creatinine , Urinalysis ( UA ) , urine toxicology , thyroid function ) . Baseline antipsychotic level collect . All woman pregnancy test , unless either surgically hormonally post menopausal . 4-Week Double Blind Treatment Phase : The study 4-week , placebo control , double blind study . Subjects randomize either : MK-0777 GEM 3mg BID ; MK-0777 GEM 8mg BID ; placebo . The unblinded site pharmacist notify treatment assignment , dispense study medication . Subjects receive biweekly symptom assessment weekly side effect vital sign assessment . At week 4 , subject undergo repeat administration neuropsychological test battery functional capacity patient self-report cognitive function measure . These assessment do two-day period . At week 4 , subject also undergo repeat slit lamp eye examination . We also attempt contact schedule subject drop study prior week 4 week 4 slit lamp eye examination . Finally , subject blood sample collect antipsychotic MK-0777 level week 4 . 6-Month 12-Month Follow-up Evaluations : All subject , regardless complete 4-week double-blind treatment phase , contact schedule follow-up slit lamp eye examination . Randomization : Subjects randomly assign placebo one two dos experimental treatment within stratum define site . Recruitment : Recruitment potential subject perform review subject record determine eligibility base inclusion exclusion criterion . Once qualify record identify , potential subject inform individually and/or group set study .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Diagnosis : DSM IV/DSM IV TR schizophrenia ( include disorganize , paranoid , undifferentiated , catatonic subtypes ) Capable provide informed consent Duration illness equal great one year Treated one two follow second generation antipsychotic : risperidone , paliperidone , olanzapine , quetiapine , ziprasidone , aripiprazole previous two month , change dose last month . Meet follow symptom criterion : Brief Psychiatric Rating Scale ( BPRS ) Hallucinatory Behavior , Unusual Thought Content Conceptual Disorganization item score ≤ 4 All Scale Assessment Negative Symptoms global item ≤ 3 SimpsonAngus Scale total score ≤ 6 Calgary Depression Scale total score ≤ 10 Meet follow cognitive performance criterion : Performance le maximum cutoff ( parenthesis ) ONE follow MCCB test : . ) Letternumber span ( 20 ) ; ii . ) HVLT total ( 31 ) ; iii . ) CPT dprime ( 3.47 ) Able complete baseline MCCB validly Raw score ≥6 WTAR Current treatment ( within 4 week ) conventional antipsychotic ( e.g . fluphenazine , haloperidol ) clozapine Current treatment psychotropic agent know act GABAA receptor , include benzodiazepine ; sedativehypnotics trazadone chloral hydrate ; carbamazepine , gabapentin , lamotrigine , valproic acid Current treatment drug inhibits CYP3A4 , include : cimetidine ; cyclosporine ; erythromycin erythromycinlike drug ( e.g. , azithromycin , clarithromycin ) ; diltiazem ; fluoxetine , fluovoxamine ; itraconazole , ketoconazole systemic antifungal agent azole class ; nefazodone ; induce CYP3A4 , include : carbamazepine , modafinil ; phenobarbital ; phenytoin ; rifampin ; St. Johns wort ; troglitazone . Current treatment psychotropic agent know effect cognition : amphetamine ; barbiturate ; lithium ; MAOIs ; methylphenidate Current treatment herbal preparation possible psychotropic effect ( e.g. , St. Johns wort , kavakava , Valerian , SAdenosyl Methionine [ SAMe ] ) Current treatment systemic steroid DSMIV diagnosis alcohol substance abuse ( nicotine ) within last month DSMIV diagnosis alcohol substance dependence within last 6 month Presence PI great posterior subcapsular cataract Uveitis 1+ great flare cell Nuclear cortical cataract History significant head injury/trauma , define one following : loss consciousness ( LOC ) 1 hour , seizures head injury , clear cognitive sequellae injury , cognitive rehabilitation follow injury History clinically significant neurological , metabolic , hepatic , renal , hematological , pulmonary , cardiovascular , gastrointestinal , and/or urological disorder . Clinically significant abnormality physical examination , ECG , laboratory assessment A positive test Hepatitis C antibody concurrent evidence impair hepatic function ( increase AST ALT great 2 time upper limit normal ) positive test Hepatitis A antibody IgM fraction Hepatitis B surface antigen , irrespective AST ALT value . Pregnant woman woman childbearing potential , either surgicallysterile use appropriate method birth control Women breastfeed History severe symptom benzodiazepine withdrawal ( e.g. , history seizure delirium associate withdrawal ) Received ECT treatment within last 3 month Participated clinical trial psychotropic medication within 2 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Cognition</keyword>
	<keyword>Schizophrenia</keyword>
</DOC>